These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 28215471

  • 21. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.
    Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, Detke MJ, Kane JM.
    J Psychiatr Res; 2014 Jun; 53():14-22. PubMed ID: 24613032
    [Abstract] [Full Text] [Related]

  • 22. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
    Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A.
    Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
    [Abstract] [Full Text] [Related]

  • 23. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder.
    Honer WG, MacEwan GW, Gendron A, Stip E, Labelle A, Williams R, Eriksson H, STACK Study Group.
    J Clin Psychiatry; 2012 Jan; 73(1):13-20. PubMed ID: 21733490
    [Abstract] [Full Text] [Related]

  • 24. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO.
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [Abstract] [Full Text] [Related]

  • 25. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
    Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG, Aripiprazole Study Group.
    J Clin Psychiatry; 2003 Sep; 64(9):1048-56. PubMed ID: 14628980
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.
    Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, Hsu J, Loebel A.
    CNS Spectr; 2014 Aug; 19(4):330-9. PubMed ID: 24330868
    [Abstract] [Full Text] [Related]

  • 27. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
    Potkin SG, Ogasa M, Cucchiaro J, Loebel A.
    Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
    [Abstract] [Full Text] [Related]

  • 28. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [Abstract] [Full Text] [Related]

  • 29. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M, Levi L, Burshtein S, Hagin M, Matei VP, Podea D, Micluția I, Tiugan A, Păcală B, Grecu IG, Noy A, Zamora D, Davis JM.
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
    Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG.
    J Clin Psychiatry; 2007 Jan; 68(1):29-36. PubMed ID: 17284127
    [Abstract] [Full Text] [Related]

  • 31. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME, Kent JM, Daly E, Janssens L, Van Osselaer N, Hüsken G, Anghelescu IG, Van Nueten L.
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [Abstract] [Full Text] [Related]

  • 32. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
    Correll CU, Kohegyi E, Zhao C, Baker RA, McQuade R, Salzman PM, Sanchez R, Nyilas M, Carson W.
    J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
    [Abstract] [Full Text] [Related]

  • 33. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW.
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [Abstract] [Full Text] [Related]

  • 34. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, Perry PP, Gara M, McQuade RD, Carson WH, Sanchez R.
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [Abstract] [Full Text] [Related]

  • 35. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group.
    Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
    [Abstract] [Full Text] [Related]

  • 36. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):61-68. PubMed ID: 28839341
    [Abstract] [Full Text] [Related]

  • 37. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, Gurvich C, Gilbert H, Berk M, Davis SR.
    JAMA Psychiatry; 2016 Sep 01; 73(9):947-54. PubMed ID: 27438995
    [Abstract] [Full Text] [Related]

  • 38. Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.
    Cantillon M, Ings R, Bhat L.
    Clin Transl Sci; 2018 Jul 01; 11(4):387-396. PubMed ID: 29637739
    [Abstract] [Full Text] [Related]

  • 39. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, Iwamoto T.
    Psychopharmacology (Berl); 2006 Oct 01; 188(3):281-92. PubMed ID: 16953381
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S.
    J Child Adolesc Psychopharmacol; 2012 Oct 01; 22(5):327-42. PubMed ID: 23083020
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.